What is NeuroBo Pharmaceuticals, Inc.'s current stock price?

NeuroBo Pharmaceuticals, Inc. (NRBO) currently trades at USD 2.36. Track real-time price changes and historical performance on AllInvestView.

What sector is NeuroBo Pharmaceuticals, Inc. in?

NeuroBo Pharmaceuticals, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

NeuroBo Pharmaceuticals, Inc. NRBO · Stock Open NeuroBo Pharmaceuticals, Inc. in new tab

2.36 USD

Add to portfolio

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for NeuroBo Pharmaceuticals, Inc. (NRBO)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

NeuroBo Pharmaceuticals, Inc. Analysis (NRBO)

United States Health Care Official Website Stock

Is NeuroBo Pharmaceuticals, Inc. a good investment? NeuroBo Pharmaceuticals, Inc. (NRBO) is currently trading at 2.36 USD.

Investor FAQ

Does NeuroBo Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is NeuroBo Pharmaceuticals, Inc.?

NeuroBo Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

Company Profile

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Exchange Ticker

MTVA

NCM (Australia) NRBO

Trades

Dividend History paid per year (USD)

No dividend history available.

Stock Splits

Split Date	Split Ratio to 1
Dec. 31, 2019	1:25
Sept. 13, 2022	0.03
Dec. 21, 2023	0.12

NeuroBo Pharmaceuticals, Inc. NRBO · Stock Open NeuroBo Pharmaceuticals, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

NeuroBo Pharmaceuticals, Inc. Analysis (NRBO)

Investor FAQ

Company Profile

Fundamentals

Under Construction

NeuroBo Pharmaceuticals, Inc. NRBO · Stock Open NeuroBo Pharmaceuticals, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

NeuroBo Pharmaceuticals, Inc. Analysis (NRBO)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications